Skip to main content
. 2014 Apr 14;2014(4):CD000227. doi: 10.1002/14651858.CD000227.pub4

Gorai 1999.

Study characteristics
Methods Random allocation
List of randomly generated treatment codes prepared by 1 of the investigators
No blinding of outcome assessors reported
Completion rate unclear
Participants Outpatient study, Japan
44 women, average age 51 years
Inclusion criteria: postmenopausal women with at least 1 year but not more than 5 years since last menses
Disease exclusions: surgical menopause, chronic disease (renal disease, hyperparathyroidism, diabetes mellitus), compression fracture on thoracic or lumbar spine radiograph
Drug exclusions: drug treatment known to affect bone metabolism
Interventions 1. 1 μg 1‐alphahydroxyvitamin D3 daily
Randomised 20, completed unclear
2. No intervention
Randomised 24, completed unclear
3. 1 μg 1‐alphahydroxyvitamin D3 and 0.625 mg conjugated oestrogen daily (group not used in this review)
4. 0.625 mg conjugated oestrogen daily (group not used in this review)
Duration of treatment 2 years
Outcomes Measured at 2 years
1. Number of persons sustaining new vertebral fracture
2. Number of persons with hypercalcaemia
3. BMD of lumbar spine and femoral neck
4. Biochemical markers of bone formation and breakdown
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence generation (selection bias) High risk States "randomly generated treatment codes previously prepared by a controller": Y Misu who was one of the investigators; no other information provided
Allocation concealment (selection bias) Unclear risk No details provided